Drug evaluation: Deferitrin (GT-56-252; NaHBED) for iron overload disorders

IDrugs

Volumn 10, Issue 4, 2007, Pages 270-281

  Barton, James C ^a,b  

^a SOUTHERN IRON DISORDERS CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIETHYL 3 HYDROXY 4 PYRIDONE; 1,6 DIMETHYL 3 HYDROXY 4 PYRIDINONE 2 CARBOXY(N METHYL)AMIDE; BISPHENOLIC TRIAZOLE; CHELATING AGENT; DEFERASIROX; DEFERIPRONE; DEFERITRIN; DEFEROXAMINE; DEFERRIFERRITHIOCIN; DESFERRITHIOCINE; HYDROXYETHYLSTARCH DEFEROXAMINE; IRON; IRON CHELATE; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; APLASTIC ANEMIA; AUTHOR; BETA THALASSEMIA; BLOOD DYSCRASIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; EYE DISEASE; GROWTH RETARDATION; HEART INJURY; HUMAN; HYPOACUSIS; INFECTION SENSITIVITY; IRON OVERLOAD; KIDNEY FAILURE; KIDNEY INJURY; LIQUID; LIVER INJURY; LUNG INJURY; MONOTHERAPY; NEUTROPENIA; NONHUMAN; RASH; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CARBOXYLIC ACIDS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG EVALUATION, PRECLINICAL; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 33947701665     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. 22787 Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: Studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores. Zevin S, Link G, Grady RW, Hider RC, Peter HH, Hershko C BLOOD 1992 79 1 248-253
2. 59494 Rapid desensitisation for desferrioxamine anaphylactic reaction. Miller KB, Rosenwasser LJ, Bessette JA, Beer DJ, Rocklin RE LANCET 1981 1 8228 1059-1060
3. 60151 Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload. Janka GE, Mohring P, Helmig M, Haas RJ, Betke K EUR J PEDIATR 1981 137 3 285-290
4. 61392 Ferrioxamine excretion in iron-loaded man. Pippard MJ, Callender ST, Finch CA BLOOD 1982 60 2 288-294
5. 75581 Effectiveness of oral iron chelators assayed in the rat. Kim BK, Huebers HA, Finch CA AM J HEMATOL 1987 24 3 277-284
6. 76152 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV LANCET 1987 1 8545 1294-1295
7. 86714 Desferrioxamine-induced iron excretion in humans. Pippard MJ BAILLIERES CLIN HAEMATOL 1989 2 2 323-343
8. 86716 The toxic effects of desferrioxamine. Porter JB, Huehns ER BAILLIERES CLIN HAEMATOL 1989 2 2 459-474
9. 90050 Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW BR J HAEMATOL 1989 73 3 403-409
10. 96727 High incidence of cardiomyopathy in β-thalassaemia patients receiving regular transfusion and iron chelation: Reversal by intensified chelation. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ ACTA HAEMATOL 1990 84 3 113-117
11. 109116 Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IY LANCET 1992 339 8795 699-701
12. 113323 Development of iron-chelating agents for clinical use. Brittenham GM BLOOD 1992 80 3 569-574
13. 124502 A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Bergeron RJ, Streiff RR, Creary EA, Daniels RD, Jr King W, Luchetta G, Wiegand J, Moerker T, Peter HH BLOOD 1993 81 8 2166-2173
14. 225898 SunPharm expands technology agreement with the University of Florida. SunPharm Inc PRESS RELEASE 1996 November 18
15. 314054 Desazadesmethyldesferrithiocin analogues as orally effective iron chelators. Bergeron RJ, Wiegand J, Weimar WR, Vinson JR, Bussenius J, Yao GW, McManis JS J MED CHEM 1999 42 1 95-108
16. 342465 Schein Pharmaceutical licenses iron chelator from SunPharm. SunPharm Corp PRESS RELEASE 1999 October 06
17. 349087 Drug development pipeline: CP94. King's College London COMPANY COMMUNICATION 1999 November 30
18. 386956 Biliary and urinary metabolic profiles of 1,2-diethyl-3- hydroxypyridin-4-one (CP94) in the rat. Lu SL, Gosriwatana I, Liu ZD, Mallet AI, Hider RC DRUG METAB DISPOS 2000 28 8 873-879
19. 393616 GelTex Pharmaceuticals announces stockholders approval of merger agreement with Genzyme Corporation. GelTex Pharmaceuticals Inc PRESS RELEASE 2000 December 13
20. 431916 Chelator-induced iron excretion in iron-overloaded marmosets. Sergejew T, Forgiarini P, Schnebli HP BR J HAEMATOL 2000 110 4 985-992
21. 456872 HBED ligand: Preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Bergeron RJ, Wiegand J, Brittenham GM BLOOD 2002 99 8 3019-3026
22. 472082 Preclinical toxicology and pharmacokinetics of GT56-252, a novel orally available iron chelator. Forster R, Aoude Dagher R, Bree M, Appelqvist T, Guillamat PO, Marquis JK TOXICOL LETT 2002 135 Suppl 1 162-163
23. 505908 Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Cohen AR, Galanello R, Piga A, De S, V, Tricta F BLOOD 2003 102 5 1583-1587
24. 512010 Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R J CLIN PHARMACOL 2003 43 6 565-572
25. 546588 Watson refocuses on urology, nephrology and generics. Watson Pharmaceuticals Inc PRESS RELEASE 2004 28 June
26. 573932 The safety and pharmacokinetics of deferitrin, a novel orally available iron chelator. Donovan JM, Yardumian A, Gunawardena KA, Plone MA, Wonke B BLOOD 2004 104 11 Abs 504
27. 581803 Clinical consequences of acquired transfusional iron overload in adults. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF N ENGL J MED 1981 304 6 319-324
28. 581809 Prolonged survival in patients with β-thalassemia major treated with deferoxamine. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW J PEDIATR 1991 118 4 Pt 1 540-545
29. 581811 Clinical manifestations and therapy of transfusional haemosiderosis. Gabutti V, Borgna-Pignatti C BAILLIERES CLIN HAEMATOL 1994 7 4 919-940
30. 581812 Pulmonary iron overload in thalassemia major presenting as small airway disease. Ooi GC, Khong PL, Lam WK, Trendell-Smith NJ, Tsang KW ACTA HAEMATOL 2002 108 1 43-46
31. 588079 Deferasirox. Barton JC CURR OPIN INVESTIG DRUGS 2005 6 3 327-335
32. 669861 Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Donovan JM, Plone M, Dagher R, Bree M, Marquis J ANN NY ACAD SCI 2005 1054 492-494
33. 669865 The safety and pharmacokinetics of GT56-252, a novel orally available iron chelator. Donovan JM, Palmer PA, Plone MA, Wonke B EUR J CLIN INVEST 2004 34 Suppl 1 39
34. 669866 Pharmocokinetics of GT56-252, novel orally available iron chelator in rat, dog and cynomolgous monkey. Marquis JK, Aoude Dagher R, Bree M, Appelqvist T, Guillaumat P, Forster P TOXICOL SCI 2003 72 Suppl 1 47
35. 670626 The design of orally active iron chelators. Hider RC, Zhou T ANN NY ACAD SCI 2005 1054 141-154
36. 670628 Repeated dose subcutaneous toxicity and toxicokinetics study of NaHBED in beagle dogs. Frantz CE, Fairchild DG, Green CE, Catz P, Phillips S, Payson E, Tyson C TOXICOL SCI 2003 72 1 Suppl Abs 49
37. 670630 28-Day iv study of NaHBED in iron-loaded and normal (unloaded) beagle dogs. Tyson CA, Fairchild DG, Green CE, Catz PG, Phillips SJ, Marquis J TOXICOL SCI 2001 60 1 Suppl 262
38. 739252 GelTex 10-K: 2000. GelTex Pharmaceuticals Inc SECURITIES AND EXCHANGE COMMISSION FORM 10-K 2000 March 30
39. 739335 Orphan products: FDA. Genzyme Corp INTERNET SITE 2004 April 14
40. 739436 NCT00069862: Iron balance study of DFO and GT56-252 in patients with transfusional iron overload secondary to β-thalassemia. Genzyme Corp www.clinicaltrials.gov 2006 January 25
41. 743217 Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI BLOOD 2006 108 9 3195-3203
42. 760258 The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, Sakellaropoulos N, Papanikolaou G HAEMATOLOGICA 2006 91 6 809-812
43. 760261 Survival in thalassaemia major patients. Efthimiadis GK, Hassapopoulou HP, Tsikaderis DD, Karvounis HI, Giannakoulas GA, Parharidis GE, Louridas GE CIRC J 2006 70 8 1037-1042
44. 760262 Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ J CARDIOVASC MAGN RESON 2006 8 3 543-547
45. 760263 Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A BLOOD 2006 107 9 3733-3737
46. 760310 Iron absorption in the thalassemia syndromes and its inhibition by tea. de Alarcon PA, Donovan ME, Forbes GB, Landaw SA, Stockman JA III N ENGL J MED 1979 300 1 5-8
47. 760311 Metabolic products of actinomycetes. XXVII. Constitutional formula of ferrioxamine B. Bickel H, Hall GE, Keller-Schierlein W, Prelog V, Vischer E, Wettstein A HELV CHIM ACTA 1960 43 2129
48. 760322 Iron-chelating therapy and the treatment of thalassemia. Olivieri NF, Brittenham GM BLOOD 1997 89 3 739-761
49. 760324 The treatment of thalassemia - slow progress and new dilemmas. Weatherall DJ N ENGL J MED 1993 329 12 877-879
50. 760326 Clinical experience of management of thalassemia: The Sardinian experience. Cao A, Galanello R, Rosatelli MC, Argiolu F, De Virgiliis S SEMIN HEMATOL 1996 33 1 66-75
51. 760332 Results of long-term iron-chelating therapy. Gabutti V, Piga A ACTA HAEMATOL 1996 95 1 26-36
52. 760335 Chelation therapy in β-thalassemia: The benefits and limitations of desferrioxamine. Giardina PJ, Grady RW SEMIN HEMATOL 1995 32 4 304-312
53. 760338 Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG N ENGL J MED 1985 312 25 1600-1603
54. 760350 Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB, Singh S DRUG METAB DISPOS 1993 21 4 640-644
55. 760351 Deferoxamine-induced growth retardation in patients with thalassemia major. De Virgiliis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M et al J PEDIATR 1988 113 4 661-669
56. 760356 Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B et al N ENGL J MED 1986 314 14 869-873
57. 760359 The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF INT J HEMATOL 1991 54 5 371-375
58. 760362 Deferoxamine-induced bone dysplasia in patients with thalassemia major. Brill PW, Winchester P, Giardina PJ, Cunningham-Rundles S AJR AM J ROENTGENOL 1991 156 3 561-565
59. 760366 Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: Clinical observations, experimental studies, and theoretical considerations. Whitten CF, Gibson GW, Good MH, Goodwin JF, Brough AJ PEDIATRICS 1965 36 3 322-335
60. 760375 Evaluation of new iron chelators for clinical use. Porter JB ACTA HAEMATOL 1996 95 1 13-25
61. 760377 New multidentate ligands. VI. Chelating tendencies of N,N′-di(2-hydroxybenzyl)ethylenediamine-N, N′-diacetic acid. L'Eplattenier F, Murase I, Martell AE J AM CHEM ASSOC 1967 89 837
62. 760378 An evaluation of the potential of HBED as an orally effective iron-chelating drug. Grady RW, Hershko C SEMIN HEMATOL 1990 27 2 105-111
63. 760379 Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters. Hershko C, Grady RW, Link G HAEMATOLOGIA (BUDAP) 1984 17 1 25-33
64. 760383 Phenolic ethylenediamine derivatives: A study of orally effective iron chelators. Hershko C, Grady RW, Link G J LAB CLIN MED 1984 103 3 337-346
65. 760384 HBED: A potential oral iron chelator. Grady RW, Hershko C ANN N Y ACAD SCI 1990 612 361-368
66. 760387 HBED: A potential alternative to deferoxamine for iron-chelating therapy. Bergeron RJ, Wiegand J, Brittenham GM BLOOD 1998 91 4 1446-1452
67. 760388 HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Bergeron RJ, Wiegand J, Brittenham GM BLOOD 1999 93 1 370-375
68. 760391 Results from a phase I clinical trial of HBED. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ ADV EXP MED BIOL 1994 356 351-359
69. 760411 Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. Bergeron RJ, Wiegand J, McManis JS, McCosar BH, Weimar WR, Brittenham GM, Smith RE J MED CHEM 1999 42 13 2432-2440
70. 760414 The origin of the differences in (R)- and (S)-desmethyl- desferrithiocin. Iron-clearing properties. Bergeron RJ, Wiegand J, Ratliff-Thompson K, Weimar WR ANN NY ACAD SCI 1998 850 202-216
71. 760415 Pharmocokinetics of GT56-252, novel orally available iron chelator in rat, dog and cynomolgous monkey. Marquis JK, Aoude Dagher R, Bree M, Appelqvist T, Guillaumat P, Forster P TOXICOL SCI 2003 72 47 1
72. 760567 Anaphylactic reaction to desferrioxamine. Athanasion A, Shepp MA, Necheles TF LANCET 1977 2 8038 616
73. 760573 Desferal (desferrioxamine) - a novel activator of connective tissue-type mast cells. Shalit M, Tedeschi A, Miadonna A, Levi-Schaffer F J ALLERGY CLIN IMMUNOL 1991 88 6 854-860
74. 760581 Oral iron chelators - development and application. Liu DY, Liu ZD, Hider RC BEST PRACT RES CLIN HAEMATOL 2002 15 2 369-384
75. 760593 Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF, Rachmilewitz EA, Hebbel RP BLOOD 1995 86 5 2008-2013
76. 760599 Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand. Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, Thakernpol K, Atisuk K, Fucharoen S, Chantraluksri U, Shalev O et al AV BR J HAEMATOL 2003 122 2 305-310
77. 760600 Efficacy and safety of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of β thalassaemia major with iron overload. Agarwal MB, Gupte SS, Vasandani D, Viswanathan C, Puniyani RR, Ramanathan J, Massil DE, Shah S, Rajyadhyaksha GC, Bhave AA J ASSOC PHYSICIANS INDIA 1991 39 9 669-672
78. 760608 The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F et al BR J HAEMATOL 2002 118 1 330-336
79. 760609 Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA N ENGL J MED 1998 339 7 417-423
80. 760610 Iron deficiency and overload. Beutler E, Hoffbrand AV, Cook JD HEMATOLOGY (AM SOC HEMATOL EDUC PROGRAM) 2003 40-61
81. 760612 Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent β-thalassemia. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR BLOOD 2002 100 5 1566-1569
82. 760613 Intracellular labile iron pools as direct targets of iron chelators: A fluorescence study of chelator action in living cells. Glickstein H, El RB, Shvartsman M, Cabantchik ZI BLOOD 2005 106 9 3242-3250
83. 760615 A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F et al BR J HAEMATOL 2007 136 3 501-508
84. 760616 A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M et al BLOOD 2006 107 9 3455-3462
85. 760617 Optimal management strategies for chronic iron overload. Barton JC DRUGS 2007 (in press)
86. 760619 A phase II study with ICL670 (Exjade), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload. Porter J, Vichinsky E, Rose C, Piga A, Olivieri N, Gatterman N, Maertens J, Rabault B, Gathmann I, Alberti D BLOOD 2004 104 11
87. 760620 Chelation therapy of iron overload. Barton JC CURR GASTROENTEROL REP 2007 (in press)
88. 760624 Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M et al J CLIN ONCOL 2005 23 30 7594-7603
89. 760626 Myelodysplastic syndromes clinical practice guidelines in oncology. Dalzell L, Orlando M, MacDonald M, Berg A, Bradley M, Cacace A, Campbell D, DeCristofaro J, Gravel J, Greenberg E, Gross S et al J NATL COMPR CANC NETW 2006 4 1 58-77
90. 760630 The efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndromes (MDS) and iron overload. Gattermann N, Cazzola M, Greenberg P, Maertens J, Soulieres D, Rose C LEUK RES 2005 29 1 S76
91. 760632 Improved survival in patients with myelodyspalastic syndrome (MDS) receiving iron chelation therapy. Leitch HA, Goodman TA, Wong KK, Vickars LM, Galbraith PF, Legar CS BLOOD 2006 108 11
92. 760635 Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases. Nielsen P, Fischer R, Buggisch P, Janka-Schaub G BR J HAEMATOL 2003 123 5 952-953
93. 766984 Esters and lactones of phenolic amino carboxylic acids: Prodrugs for iron chelation. Pitt CG, Bao Y, Thompson J, Wani MC, Rosenkrantz H, Metterville J J MED CHEM 1986 29 7 1231-1237
94. 767004 A comparative evaluation of iron chelators in a primate model. Peter HH, Bergeron RJ, Streiff RR, Weigand J. In: Bergeron RJ, Brittenham GM THE DEVELOPMENT OF IRON CHELATORS FOR CLINICAL USE. Boca Raton: CRC Press 1994 373
95. 767005 Preliminary results from a phase I clinical trial of HBED. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ. In: Bergeron RJ, Brittenham THE DEVELOPMENT OF IRON CHELATORS FOR CLINICAL USE. Boca Raton: CRC Press 1994 395
96. 767011 Synthesis of N,N′-di(2-hydroxybenzyl) ethylenediamine-N,N′-diacetic acid (HBED) and derivatives. Martell AE, Motekaitis RJ, Clarke ET, Harrison JJ CAN J CHEM 1986 64 449-456
97. 767043 Exjade (deferasirox) prescribing information. Novartis Pharma Corp 2006
98. 768115 Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in β-thalassaemia. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ LANCET 2002 360 9332 516-520
99. 3+ values. Liu ZD, Piyamongkol S, Liu DY, Khodr HH, Lu SL, Hider RC BIOORG MED CHEM 2001 9 3 563-573
100. 768154 Metabolic and pharmacokinetic evaluation of a novel 3-hydroxypyridinone iron chelator, CP502, in the rat. Novakovic J, Tesoro A, Thiessen JJ, Spino M EUR J DRUG METAB PHARMACOKINET 2004 29 4 221-224
101. 768163 First human studies with a high-molecular-weight iron chelator. Dragsten PR, Hallaway PE, Hanson GJ, Berger AE, Bernard B, Hedlund BE J LAB CLIN MED 2000 135 1 57-65
102. 768167 DMT1: A mammalian transporter for multiple metals. Garrick MD, Dolan KG, Horbinski C, Ghio AJ, Higgins D, Porubcin M, Moore EG, Hainsworth LN, Umbreit JN, Conrad ME, Feng L et al BIOMETALS 2003 16 1 41-54
103. 768169 Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. Wetli HA, Buckett PD, Wessling-Resnick M CHEM BIOL 2006 13 9 965-972
104. 2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Ludwiczek S, Theurl I, Muckenthaler MU, Jakab M, Mair SM, Theurl M, Kiss J, Paulmichl M, Hentze MW, Ritter M, Weiss G NAT MED 2007 February 11 [epublished ahead of print]
105. 768171 Drug Discovery Programs - DMT1. Xenon Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2007 February 23